- Home
- ORKA vs EYPT Comparison
ORKA vs EYPT Comparison
Compare ORKA & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKA
- EYPT
- Stock Information
- Founded
- ORKA 2004
- EYPT 1987
- Country
- ORKA United States
- EYPT United States
- Employees
- ORKA N/A
- EYPT N/A
- Industry
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- ORKA Health Care
- EYPT Industrials
- Exchange
- ORKA Nasdaq
- EYPT Nasdaq
- Market Cap
- ORKA 516.3M
- EYPT 579.4M
- IPO Year
- ORKA N/A
- EYPT 2005
- Fundamental
- Price
- ORKA $13.60
- EYPT $9.71
- Analyst Decision
- ORKA Strong Buy
- EYPT Strong Buy
- Analyst Count
- ORKA 8
- EYPT 8
- Target Price
- ORKA $39.71
- EYPT $24.75
- AVG Volume (30 Days)
- ORKA 166.5K
- EYPT 636.8K
- Earning Date
- ORKA 08-15-2025
- EYPT 08-06-2025
- Dividend Yield
- ORKA N/A
- EYPT N/A
- EPS Growth
- ORKA N/A
- EYPT N/A
- EPS
- ORKA N/A
- EYPT N/A
- Revenue
- ORKA N/A
- EYPT $56,042,000.00
- Revenue This Year
- ORKA N/A
- EYPT N/A
- Revenue Next Year
- ORKA N/A
- EYPT N/A
- P/E Ratio
- ORKA N/A
- EYPT N/A
- Revenue Growth
- ORKA N/A
- EYPT 12.04
- 52 Week Low
- ORKA $5.49
- EYPT $3.91
- 52 Week High
- ORKA $52.32
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- ORKA N/A
- EYPT 47.87
- Support Level
- ORKA N/A
- EYPT $9.77
- Resistance Level
- ORKA N/A
- EYPT $10.41
- Average True Range (ATR)
- ORKA 0.00
- EYPT 0.52
- MACD
- ORKA 0.00
- EYPT -0.17
- Stochastic Oscillator
- ORKA 0.00
- EYPT 8.58
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.